Skip to Content
Get key facts and figures about chronic dry eye

Verteporfin Pregnancy and Breastfeeding Warnings

Verteporfin is also known as: Visudyne

Verteporfin Pregnancy Warnings

Verteporfin has been assigned to pregnancy category C by the FDA. Animal studies have demonstrated anophthalmia and microphthalmia with high doses. There are no controlled data in human pregnancy. Verteporfin is only recommended for use during pregnancy when benefit outweighs risk.

See references

Verteporfin Breastfeeding Warnings

Verteporfin is excreted into human milk. The effects in the nursing infant are unknown. Because of the potential for serious adverse reactions in nursing infants from verteporfin, a decision should be made whether to discontinue nursing or postpone treatment, taking into account the importance of the drug to the mother.

Verteporfin and its diacid metabolite have been found human breast milk after a 6 mg/m2 infusion. The verteporfin breast milk levels were up to 66% of the corresponding plasma levels and declined below the limit of quantification (2 ng/mL) within 24 hours. The diacid metabolite had lower peak concentrations but persisted up to at least 48 hours.

See references

References for pregnancy information

  1. "Product Information. Visudyne (verteporfin)" Ciba Vision Ophthalmics, Duluth, GA.

References for breastfeeding information

  1. "Product Information. Visudyne (verteporfin)" Ciba Vision Ophthalmics, Duluth, GA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.